2023 ABAI Continuous Assessment Program Literature Review - February-July
This literature review course, originally presented as part of the 2023 AAAAI Annual Meeting, will help to prepare ABAI diplomates to participate in the Continuous Assessment Program (CAP). The course will include reviews of the journal articles selected for the January-June 2021 term of the CAP to help develop greater familiarity with the key concepts included in them.
The five presentations cover a range of critical journal articles in the following topic areas:
- Food and Drug Allergy/Hypersensitivity Reactions and Eosinophilic or Gastrointestinal Disorders
- Conditions of the Head/Neck and Lungs
- Dermatologic Conditions and Anaphylaxis
- Immune Hypersensitivity Disorders and Immunodeficiencies
- Emerging National Health Priorities
Click the Program tab to access the full list of articles, with links. Please note that all CAP articles can be accessed through the ABAI web portal.
- Allergist/Immunologists participating in continuous certification with the American Board of Allergy & Immunology
- Allied health providers working in allergy/immunology settings
- Allergy/Immunology Fellows-in-Training preparing for initial certification
- Other healthcare providers with an interest in allergy/immunology
Upon completion of this activity, participants should be able to:
- Evaluate recently published research relevant to the practice of allergy/immunology
All CAP articles are listed, below.
Articles can be accessed through the ABAI web portal.
CAP 2023 – Block 1 Article-based Reference List
Borish L, et al. Yardstick for the medical management of chronic rhinosinusitis. Annals of Allergy, Asthma & Immunology. 2022;128(2):118-128. https://doi.org/10.1016/doi:10.1016/j.anai.2021.10.014
Mullol J, et al. Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(4):1086-1095.e5. https://doi.org/10.1016/j.jaip.2021.09.037
Oykhman P, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. Journal of Allergy and Clinical Immunology. 2022;149(4):1286-1295. https://doi.org/10.1016/j.jaci.2021.09.009
Smith SS, Kim R, Douglas R. Is there a role for antibiotics in the treatment of chronic rhinosinusitis? Journal of Allergy and Clinical Immunology. 2022;149(5):1504-1512. https://doi.org/10.1016/j.jaci.2022.02.004
Baeza ML, et al. Angioedema due to acquired deficiency of C1-inhibitor: A cohort study in Spain and a comparison with other series. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(4):1020-1028. https://doi.org/10.1016/j.jaip.2021.11.018
Johansen JD, et al. Novel insights into contact dermatitis. Journal of Allergy and Clinical Immunology. 2022;149(4):1162-1171. https://doi.org/10.1016/j.jaci.2022.02.002
Khan DA, et al. What’s new in the treatment of urticaria and angioedema. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(6):2170-2184. https://doi.org/10.1016/j.jaip.2021.03.012
Singh AM, et al. Atopic dermatitis and food allergy: Best practices and knowledge gaps—a work group report from the AAAAI Allergic Skin Diseases Committee and Leadership Institute Project. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(3):697-706. https://doi.org/10.1016/j.jaip.2021.12.037
Brennan V, et al. The contribution of oral and inhaled glucocorticoids to adrenal insufficiency in asthma. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(10): 2614-2623. https://doi.org/10.1016/j.jaip.2022.05.031
Hurrell BP, et al. Cannabinoid receptor 2 engagement promotes group 2 innate lymphoid cell expansion and enhances airway hyperreactivity. Journal of Allergy and Clinical Immunology. 2022;149(5):1628-1642.e10. https://doi.org/10.1016/j.jaci.2021.09.037
Wilson K, et al. The association between duration of breastfeeding and childhood asthma outcomes. Annals of Allergy, Asthma & Immunology. 2022;129(2):205-211. https://doi.org/10.1016/j.anai.2022.04.034
A4 Food and Drug Allergy/Hypersensitivity Reactions
González-Delgado P, et al. Food protein–induced enterocolitis syndrome in adulthood: Clinical characteristics, prognosis, and risk factors. The Journal of Allergy and Clinical Immunology: In Practice. 2022. https://doi.org/10.1016/j.jaip.2022.05.006
Li L, et al. Safety, outcomes, and recommendations for two-step outpatient nonsteroidal anti-inflammatory drug challenges. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(5):1286-1292.e2. https://doi.org/10.1016/j.jaip.2021.11.006
Peters RL, et al. The natural history of peanut and egg allergy in children up to age 6 years in the HealthNuts population-based longitudinal study. Journal of Allergy and Clinical Immunology. 2022;150(3):657-665.E13. https://doi.org/10.1016/j.jaci.2022.04.008
van der Poorten M-LM, et al. Reliability of early and late testing for suspected perioperative hypersensitivity. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(4):1057-1062.e2. https://doi.org/10.1016/j.jaip.2021.10.066
Carra S, et al. Anaphylaxis and pregnancy: A systematic review and call for Public Health Actions. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(12):4270-4278. https://doi.org/10.1016/j.jaip.2021.07.046
Cuevas-Bravo C, et al. Kounis syndrome. Annals of Allergy, Asthma & Immunology. 2022;129(2):252-253. https://doi.org/10.1016/j.anai.2022.05.021
Gotlib J, et al. Proposed European Competence Network on mastocytosis—american initiative in mast cell diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(8):2025-2038.E1. https://doi.org/10.1016/j.jaip.2022.05.034
Meir LR, et al. Anaphylaxis among elderly emergency department patients in a large health system in New York. Annals of Allergy, Asthma & Immunology. 2022;129(1):63-70.e3. https://doi.org/10.1016/j.anai.2022.03.020
B1 Immune Hypersensitivity Disorders
Fijen LM, et al. Inhibition of prekallikrein for hereditary angioedema. New England Journal of Medicine. 2022;386(11):1026-1033. https://doi.org/10.1056/nejmoa2109329
Requena G, et al. Clinical profile and treatment in hypereosinophilic syndrome variants: A pragmatic review. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(8):2125-2134. https://doi.org/10.1016/j.jaip.2022.03.034
Schuppan D, et al. A randomized trial of a transglutaminase 2 inhibitor for celiac disease. New England Journal of Medicine. 2021;385(1):35-45. https://doi.org/10.1056/nejmoa2032441
Barmettler S, et al. Response to severe acute respiratory syndrome coronavirus 2 initial series and additional dose vaccine in patients with predominant antibody deficiency. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(6):1622-1634.e4. https://doi.org/10.1016/j.jaip.2022.03.017
Eddens T, et al. Trends in pediatric primary immunodeficiency: Incidence, utilization, transplantation, and mortality. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(1):286-296.e3. https://doi.org/10.1016/j.jaip.2021.10.033
LaBere B, et al. Chronic granulomatous disease with inflammatory bowel disease: Clinical presentation, treatment, and outcomes from the USIDNET Registry. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(5):1325-1333.e5. https://doi.org/10.1016/j.jaip.2021.12.035
Lee TK, Gereige JD, Maglione PJ. State-of-the-art diagnostic evaluation of common variable immunodeficiency. Annals of Allergy, Asthma & Immunology. 2021;127(1):19-27. https://doi.org/10.1016/j.anai.2021.03.005
B3 Eosinophilic or Gastrointestinal Disorders
Chen MM, et al. An international, retrospective study of off-label biologic use in the treatment of hypereosinophilic syndromes. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(5):1217-1228.e3. https://doi.org/10.1016/j.jaip.2022.02.006
Dellon ES, Simon D, Wechsler ME. Controversies in allergy: The potential role of biologics as first-line therapy in eosinophilic disorders. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(5):1169-1176. https://doi.org/10.1016/j.jaip.2022.01.043
Leiferman KM, Peters MS. Eosinophil-related disease and the skin. The Journal of Allergy and Clinical Immunology: In Practice. 2018;6(5):1462-1482.e6. https://doi.org/10.1016/j.jaip.2018.06.002
Muir AB, et al. Esophageal remodeling in eosinophilic esophagitis: Relationships to luminal captured biomarkers of inflammation and Periostin. Journal of Allergy and Clinical Immunology. 2022;150(3):649-656.E5. https://doi.org/10.1016/j.jaci.2022.03.022
C Emerging National Health Priorities
Biagini JM, et al. Longitudinal atopic dermatitis endotypes: An atopic march paradigm that includes Black Children. Journal of Allergy and Clinical Immunology. 2022;149(5):1702-1710.E4. https://doi.org/10.1016/j.jaci.2021.09.036
Israel E, et al. Reliever-triggered inhaled glucocorticoid in black and Latinx adults with asthma. New England Journal of Medicine. 2022;386(16):1505-1518. https://doi.org/10.1056/nejmoa2118813
Magnus MC, et al. Association of SARS-COV-2 vaccination during pregnancy with pregnancy outcomes. JAMA. 2022;327(15):1469-1477. https://doi.org/10.1001/jama.2022.3271
Sullivan DJ, et al. Early outpatient treatment for covid-19 with convalescent plasma. New England Journal of Medicine. 2022;386(18):1700-1711. https://doi.org/10.1056/nejmoa2119657
Programmed by the 2022-2023 AAAAI Annual Meeting Program Committee
Committee member financial disclosures are available for review here
Yamini Virkud, MD FAAAAI
University of North Carolina, Chapel Hill, NC
Relevant relationships: None
Anju T. Peters, MD MSCI FAAAAI
Northwestern University Medical School, Chicago, IL
Relevant relationships: None
John Kelso, MD FAAAAI
Scripps Clinic, La Jolla, CA
Relevant relationships: None
Yasmin W. Khan, MD
Vanderbilt University Medical Center, Nashville, TN
Relevant relationships: None
David R. Stukus, MD FAAAAI
Nationwide Children's Hospital, Columbus, OH
Relevant relationships: None
All relevant relationships disclosed by planners and faculty have been mitigated.
AAAAI Disclosure Policy
Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, planners and presenters are required to disclose all relationships that meet the following parameters:
- Employment. Name of employer and job title.
- Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
- Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
- Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
- Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
- Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
- Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.
The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at firstname.lastname@example.org.
Original release date: April 1, 2023. Valid for credit through July 31, 2023.
Activity-related questions should be directed to email@example.com.
- 2.00 AttendanceAttendance credit.
- 2.00 CMECME credit.